Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Skelaxin Moves Closer As King Loses Patent Case; Last Hurdle Is FDA

Executive Summary

Following a win in its patent case against King, Sandoz appears to have only one hurdle remaining before it can launch a generic of Skelaxin (metaxalone) - FDA approval of its ANDA

You may also be interested in...



Sandoz Tries An Authorized Generic Argument To Relaunch At-Risk Skelaxin

A temporary restraining order is blocking Sandoz's generic version of King's muscle relaxant, but CorePharma's launch of an authorized generic means the TRO should be lifted, Sandoz argues.

King Confident Of Embeda Opioid Approval In 2009; REMS Is The Final Hurdle

King Pharmaceuticals believes the FDA review of its abuse-resistant painkiller Embeda is "substantially complete," and that the company will be able to launch the drug in 2009, CEO Brian Markison assured investors during an earnings call Feb. 26

King Confident Of Embeda Opioid Approval In 2009; REMS Is The Final Hurdle

King Pharmaceuticals believes the FDA review of its abuse-resistant painkiller Embeda is "substantially complete," and that the company will be able to launch the drug in 2009, CEO Brian Markison assured investors during an earnings call Feb. 26

Related Content

Topics

UsernamePublicRestriction

Register

PS050591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel